Long-term Safety and Effectiveness of Cold-Crosslinked Hyaluronic Acid Fillers: Multicenter, Randomized, Controlled, Double-Blind Study
Aesthetic Surgery Journal · 15.07.2025 · 45 (8) · 842-849
DOI: 10.1093/asj/sjaf080 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Aesthetic Surgery Journal, online erschienen am 16.05.2025. Verfasst von Michael S Kaminer und 7 weiteren Autor:innen. Hauptthemen laut MEDLINE: Hyaluronic Acid, Skin Aging, Dermal Fillers, Cosmetic Techniques. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Symatese (Chaponost, France), Evolus Inc. (Newport Beach, CA).
Abstract (Originalsprache)
Background
Evolysse Form (EVLF) and Evolysse Smooth (EVLS) (Symatese, Chaponost, France) are new hyaluronic acid fillers created using an innovative cold-crosslinking process.
Objectives
The authors of this study aim to collect safety and effectiveness data on new cold-crosslinked fillers to support the US approval for the correction of moderate-to-severe dynamic facial wrinkles and folds.
Methods
In this randomized, controlled, split-face study, 140 patients with moderate-to-severe nasolabial folds (NLFs) received a cold-crosslinked filler in 1 NLF (EVLF = 70, EVLS = 70) and a traditionally crosslinked filler, Restylane-L (RESL), in the contralateral fold and were followed through 12 months with an optional retreatment at that time point and subsequent 3 months of safety follow-up.
Results
The primary endpoint of mean Wrinkle Severity Rating Scale change from baseline to Month 6 as rated by the photographic review panel demonstrated noninferiority and statistical superiority for the cold-crosslinked fillers. Blinded evaluator Wrinkle Severity Rating Scale assessments showed a mean change from baseline that was statistically significantly better than RESL for EVLF at all visits through 12 months and for EVLS at 6 and 9 months. Most patients were responders on the Global Aesthetic Improvement Scale throughout the study, according to ratings by blinded evaluators, treating investigators, and patients. The FACE-Q appraisal of NLFs’ overall mean score showed significant improvement from baseline (P < .0001) at all time points through Month 12 for all treatment groups. All treatments were well tolerated.
Conclusions
The new cold-crosslinked fillers were shown to be safe and effective for correction of NLFs, with results lasting for 1 year. Level of Evidence: 1 (Therapeutic)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
ORCID-Profile: Michael S Kaminer, Valerie Callender, Jeremy B Green
Förderung
- Symatese (Chaponost, France)
- Evolus Inc. (Newport Beach, CA)
Zitieren
APA
Kaminer, M. S., Avelar, R. L., Baumann, L., Callender, V., Dayan, S. H., Green, J. B., Grekin, S. K., & Guyon, S. (2025). Long-term Safety and Effectiveness of Cold-Crosslinked Hyaluronic Acid Fillers: Multicenter, Randomized, Controlled, Double-Blind Study. Aesthetic Surgery Journal, 45(8), 842-849. https://doi.org/10.1093/asj/sjaf080
Vancouver
Kaminer MS, Avelar RL, Baumann L, Callender V, Dayan SH, Green JB, et al. Long-term Safety and Effectiveness of Cold-Crosslinked Hyaluronic Acid Fillers: Multicenter, Randomized, Controlled, Double-Blind Study. Aesthetic Surgery Journal. 2025;45(8):842-849. doi:10.1093/asj/sjaf080
BibTeX
@article{Kaminer2025,
author = {Kaminer, Michael S and Avelar, Rui L and Baumann, Leslie and Callender, Valerie and Dayan, Steven H and Green, Jeremy B and Grekin, Steven K and Guyon, Sebastien},
title = {Long-term Safety and Effectiveness of Cold-Crosslinked Hyaluronic Acid Fillers: Multicenter, Randomized, Controlled, Double-Blind Study},
journal = {Aesthetic Surgery Journal},
year = {2025},
volume = {45},
number = {8},
pages = {842--849},
doi = {10.1093/asj/sjaf080}
}
EUVIMED